CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
Gwan Gyu Song, Sang-Cheol Bae, Young Ho Lee
Korean J Intern Med. 2014;29(5):656-663.   Published online 2014 August 28    DOI: https://doi.org/10.3904/kjim.2014.29.5.656

Excel Download

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
The Korean Journal of Internal Medicine. 2014;29(5):656   Crossref logo
Link1 Link2

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs: OPAL Broaden, a randomized, placebo-controlled, phase 3 trial
Journal of the American Academy of Dermatology. 2017;76(6):AB114   Crossref logo
Link1 Link2

Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
Rheumatology International. 2015;35(12):1965-1974   Crossref logo
Link1 Link2 Link3

Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies
BMC Musculoskeletal Disorders. 2013;14(1):   Crossref logo
Link1 Link2 Link3 Link4

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Arthritis Care & Research. 2017;69(4):592-598   Crossref logo
Link1 Link2 Link3 Link4 Link5

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Arthritis & Rheumatism. 2012;64(3):617-629   Crossref logo
Link1 Link2 Link3

Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance
Drugs & Aging. 2016;33(6):387-398   Crossref logo
Link1 Link2 Link3

Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis
Clinical Rheumatology. 2014;33(2):165-173   Crossref logo
Link1 Link2 Link3

Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: Meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons
Arthritis & Rheumatism. 2010;62(10):2852-2863   Crossref logo
Link1

Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis
rheuma plus. 2018;17(3):103-105   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Intern Med has participated in CrossRef Text and Data Mining service since August 31, 2015.